|
ATE273695T1
(de)
|
2000-06-28 |
2004-09-15 |
Smithkline Beecham Plc |
Nassvermahlung
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
US20070219223A1
(en)
|
2006-03-07 |
2007-09-20 |
Endacea, Inc. |
Compositions and methods for treating respiratory disorders
|
|
US8058227B2
(en)
|
2006-10-03 |
2011-11-15 |
Medical University Of South Carolina |
Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
EP2684564A1
(en)
|
2008-04-17 |
2014-01-15 |
Sanofi |
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
|
|
JP5775070B2
(ja)
|
2009-05-22 |
2015-09-09 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
PE20121336A1
(es)
|
2009-12-01 |
2012-11-03 |
Abbvie Inc |
Nuevos compuestos triciclicos
|
|
PT3354652T
(pt)
|
2010-03-10 |
2020-07-20 |
Incyte Holdings Corp |
Derivados de piperidin-4-ilazetidina como inibidores de jak1
|
|
RU2013120966A
(ru)
|
2010-10-08 |
2014-11-20 |
Эббви Инк. |
ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
AU2013274030B2
(en)
|
2012-06-15 |
2016-07-07 |
Sun Pharmaceutical Industries, Inc. |
Deuterated derivatives of ruxolitinib
|
|
CA2880083A1
(en)
|
2012-08-17 |
2014-02-20 |
Concert Pharmaceuticals, Inc. |
Deuterated baricitinib
|
|
CN104918945B
(zh)
|
2012-11-01 |
2018-01-05 |
因赛特公司 |
作为jak抑制剂的三环稠合噻吩衍生物
|
|
WO2014138168A1
(en)
|
2013-03-06 |
2014-09-12 |
Incyte Corporation |
Processes and intermediates for making a jak inhibitor
|
|
SMT201900223T1
(it)
|
2013-05-17 |
2019-07-11 |
Incyte Corp |
Sale di bipirazolo come inibitore di jak
|
|
SG10201801069QA
(en)
*
|
2013-08-07 |
2018-03-28 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
EP3060234A1
(en)
*
|
2013-10-24 |
2016-08-31 |
AbbVie Inc. |
Jak1 selective inhibitor and uses thereof
|
|
JP6576941B2
(ja)
*
|
2014-02-28 |
2019-09-18 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
骨髄異形成症候群の治療のためのｊａｋ１阻害剤
|
|
CN106687462A
(zh)
|
2014-04-30 |
2017-05-17 |
因赛特公司 |
Jak1抑制剂的制备方法以及其新形式
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
HK1252685A1
(zh)
|
2015-11-03 |
2019-05-31 |
Theravance Biopharma R&D Ip, Llc |
用於治疗呼吸疾病的jak激酶抑制剂化合物
|
|
CN105294699B
(zh)
*
|
2015-12-04 |
2019-06-11 |
上海勋和医药科技有限公司 |
巴瑞替尼的制备方法
|
|
KR102399848B1
(ko)
*
|
2016-10-03 |
2022-05-19 |
하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 |
신규한 jak1 선택적 억제제 및 그 용도
|
|
EP3327020A1
(en)
*
|
2016-11-29 |
2018-05-30 |
Sandoz Ag |
Citrate salts of a janus kinase (jak) inhibitor
|
|
BR112019018648A2
(pt)
|
2017-03-09 |
2020-06-16 |
Theravance Biopharma R&D Ip, Llc |
Inibidores de jak contendo uma amida heterocíclica com 4 membros
|
|
US10406148B2
(en)
|
2017-05-01 |
2019-09-10 |
Theravance Biopharma R&D Ip, Llc |
Methods of treatment using a JAK inhibitor compound
|
|
AR111495A1
(es)
|
2017-05-01 |
2019-07-17 |
Theravance Biopharma R&D Ip Llc |
Compuestos de imidazo-piperidina fusionada como inhibidores de jak
|
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
|
IL311485B1
(en)
|
2018-02-16 |
2026-01-01 |
Incyte Corp |
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
|
|
MD3773593T2
(ro)
|
2018-03-30 |
2024-10-31 |
Incyte Corp |
Tratament hidradenitei supurative utilizând inhibitori ai JAK
|
|
CA3097025A1
(en)
|
2018-04-13 |
2019-10-17 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
CA3117969A1
(en)
|
2018-10-31 |
2020-05-07 |
Incyte Corporation |
Combination therapy for treatment of hematological diseases
|
|
CA3123596A1
(en)
|
2018-12-19 |
2020-06-25 |
Incyte Corporation |
Jak1 pathway inhibitors for the treatment of gastrointestinal disease
|
|
MA55201A
(fr)
|
2019-03-05 |
2022-01-12 |
Incyte Corp |
Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
|
|
US11624751B2
(en)
|
2019-03-19 |
2023-04-11 |
Incyte Corporation |
Biomarkers for vitiligo
|